Bullous Keratopathy Market | Understanding the Impact of Corneal Blindness Worldwide

In 2022, the global Bullous Keratopathy Market Size was estimated to be worth US$ 410 million. The market is expected to be worth US$ 427.54 million by 2023. During the assessment period of 2023 to 2033, a CAGR of 4.3% is expected, with a closing value of US$ 650 million. The rising prevalence of ophthalmic diseases, such as keratoconus, Fuchs dystrophy, and infectious keratitis, is the key factor propelling the industry’s growth. According to the NCBI report, approximately 10-15% of patients diagnosed with keratoconus require to undergo a corneal implant procedure at some point.

Unlock growth potential with industry expertise. Download your market sample report now: https://www.futuremarketinsights.com/reports/sample/rep-gb-16131

Corneal blindness, which affects 10 million people worldwide, is the third biggest cause of blindness after glaucoma and cataract. Eye surgery is the most prevalent cause of endothelial layer of the cornea damage. Bullous Keratopathy can be caused by trauma, glaucoma, or inflammation from eye surgery. Bullous Keratopathy may occur in 1% to 2% of patients after cataract surgery, a small amount when compared to the 10 million patients who undergo cataract surgery worldwide each year.

Because of their advantages, such as low cost, biocompatibility, and enhanced safety and effectiveness, collagen-based bio-engineered artificial corneas used in Bullous Keratopathy are in great demand in the market. Manufacturers are putting more emphasis on developing and launching new products. Two items are currently in clinical testing and are projected to contribute to the artificial cornea segment and overall market growth throughout the forecast period. Corneat Vision, for example, stated in 2022 that its CorNeat KPro (artificial cornea) is undergoing clinical trials. This medicine is likely to be approved for commercialization in 2024, assisting in the market expansion of Bullous Keratopathy.

Corneal transplantation is the most important treatment for Bullous Keratopathy because it restores endothelial cell shape and function. Penetrating keratoplasty (PK), Descemet membrane endothelial keratoplasty (DMEK), or Descemet stripping automated endothelial keratoplasty (DSAEK) are all options. Between 1999 and 2001, members of the Japan Cornea Society conducted a cross-sectional national survey on 963 eyes with Bullous Keratopathy in Japan. The study looked at demographics, surgical type, complications, and postoperative outcomes. During the study period, Bullous Keratopathy accounted for 24.2% (963 eyes) of total keratoplasties performed (Shimazaki et al., 2007).

Bullous Keratopathy Market Report Available At a Discounted Price: https://www.futuremarketinsights.com/request-discount/rep-gb-16131

Key Takeaways from the Market Study:

• By 2033, the global Bullous Keratopathy market is expected to be worth USD 650 million.
• During the projection period, North America is expected to have the largest market share.
• Europe Bullous Keratopathy accounted for 19.1% of the market in 2022.
• Amniotic membrane transplantation is an effective treatment for Bullous Keratopathy that improves visual acuity and reduces subjective symptoms by influencing the process of corneal repair.
• The hospital segment dominated the market by end-user, accounting for $150 million in sales.

“With major breakthroughs in ophthalmology becoming evident, the scope for Bullous Keratopathy is expected to rise significantly. Moreover, healthcare practitioners are gravitating towards more precise surgeries to improve patient outcomes,” remarks an analyst at FMI.

Competitive Landscape:

Key players:

1. Hoffmann-La Roche Ltd
2. Regeneron Pharmaceuticals
3. Pfizer Inc.
4. Bayer AG
5. Cellusion
6. CRSTEurope
7. Barraquer Eye Hospital
8. Planchard Eye & Laser Center
9. Medscape

Some recent developments in Bullous Keratopathy market are:

• In September 2022: Celregen and Cellusion Inc. signed an exclusive license agreement for corneal endothelial cell regenerative therapy in Greater China.
• In July 2022: Carl Zeiss Meditec and Precise Bio announced a partnership in the development and commercialization of tissue-based implants for ophthalmology

Customize Your Report Now: https://www.futuremarketinsights.com/customization-available/rep-gb-16131

More Valuable Insights 

Future Market Insights, in its new offering, presents an unbiased analysis of the global Embolization Coils market, presenting historical analysis from 2017 to 2021 and forecast statistics for the period of 2022 to 2032.

The study reveals essential insights on the basis of Therapies (Emmecell, Cellusion), By Treatment [ Medical Management (Lubricants, Steroids, Hyperosmotic Agents, Anti-glaucoma Drugs, Antibiotics, Amniotic Membrane Grafting, Annular Keratotomy, Anterior Stromal Puncture)], By End-users (Hospitals, Surgical centers), By Region (North America, Latin America, Europe, South Asia & Pacific, East Asia, MEA)

About Future Market Insights, Inc.

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs